Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cyclin-dependent kinases (CDKs) are crucial for cell cycle control and transcription.
• CDK dysregulation is a hallmark of many human cancers, making them key therapeutic targets.
• Conventional CDK inhibitors face challenges like resistance and off-target effects.

Purpose of the Study:

• To review clinical and preclinical advancements in PROTACs and molecular glues targeting CDKs.
• To analyze the current landscape of CDK-targeted cancer therapies.
• To explore the molecular basis of CDK dysregulation and compare novel degradation strategies with traditional inhibitors.

Main Methods:

• Literature review of clinical and preclinical studies on CDK-targeting agents.
• Analysis of molecular mechanisms underlying CDK dysregulation in cancer.
• Comparative assessment of targeted protein degradation techniques versus conventional inhibitors.

Main Results:

• PROTACs and molecular glues offer specific degradation of CDK proteins, reducing scaffolding and kinase activity.
• These novel approaches show potential to overcome resistance mechanisms and off-target effects associated with traditional inhibitors.
• The development of these agents represents a significant shift in CDK-targeted cancer therapy.

Conclusions:

• Targeted protein degradation via PROTACs and molecular glues presents a promising new frontier in oncology.
• These strategies offer enhanced specificity and efficacy for blocking oncogenic CDK signaling.
• Further research and clinical integration are essential for realizing the full potential of these innovative cancer therapies.